[Zoledronic acid and osseous pathologies in the course of neoplasia. Part II].
Caffo
Orazio
O
Divisione di Oncologia Medica, Ospedale Santa Chiara, Trento.
D015519:Bone Density / Q000187:drug effects / Q000528:radiation effects; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000209:etiology / Q000556:secondary*; D004164:Diphosphonates / Q000627:therapeutic use*; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008297:Male; D011471:Prostatic Neoplasms / Q000473:pathology; D000077211:Zoledronic Acid
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid